Polymorphisms on 8q24 Are Associated with Lung Cancer Risk and Survival in Han Chinese

Xuelin Zhang1,3, Qun Chen2,3, Chunya He3,9, Weihua Mao1, Ling Zhang4, Xiaowen Xu1, Junfei Zhu5, Baofu Chen1,6, *

1 Department of Thoracic Surgery, Taizhou Central Hospital, Taizhou, Zhejiang, China, 2 Department of Oncology, Fuzhou Pulmonary Hospital, Fujian Medical University, Fuzhou, Fujian, China, 3 Department of Surgical Oncology, Taizhou Central Hospital, Taizhou, Zhejiang, China, 4 Department of Gynaecology and Obstetrics, Taizhou Central Hospital, Taizhou, Zhejiang, China, 5 Department of Respiratory Medicine, Taizhou Central Hospital, Taizhou, Zhejiang, China, 6 Department of Thoracic Surgery, Taizhou Hospital, Taizhou, Zhejiang, China

Abstract

Chromosome 8q24 is commonly amplified in many types of cancer, particularly lung cancer. Polymorphisms in this region are associated with risk of different cancers. To investigate the relationship between three single nucleotide polymorphisms (SNPs) (rs1447295, rs16901979 and rs6983267) on 8q24 and lung cancer risk, we conducted an association study in two Han Chinese populations: one population was from Zhejiang Province (576 case patients and 576 control subjects), whereas the other was from Fujian Province (576 case patients and 576 control subjects). We found that rs6983267 was significantly associated with an increased risk of lung cancer in both populations. Compared with the TT genotype, the GG genotype was associated with a significant 1.555-fold increased risk of lung cancer (95% confidence interval (CI) 1.218–1.986, P = 4.0 × 10^{-4}). This effect was more pronounced in never-smokers (odds ratio (OR) = 2.366, 95% CI 1.605–3.488, P = 1.4 × 10^{-4}). Analyses stratified by histology revealed that rs6983267 GG genotype was most associated with patients with other histological types (OR = 3.012, 95% CI 1.675–5.417, P = 2.3 × 10^{-4}). The AA genotype of rs1447295 was associated with increased risk of adenocarcinoma compared with the CC genotype (OR = 2.260, 95% CI 1.174–4.353, P = 0.015). Furthermore, the GG genotype of rs6983267 was associated with worse survival in the Zhejiang population (hazard ratio (HR) = 1.646, 95% CI 1.099–2.464, P = 0.016). No association was observed for rs16901979. These results suggest that genetic variations on 8q24 may play significant roles in the development and progression of lung cancer.

Introduction

Lung cancer continues to be the leading cause of cancer-related death in both men and women worldwide. In China, lung cancer accounted for 536,407 new cases of cancer and 475,768 deaths registered in 2005 [1]. In recent decades, the incidence and mortality rates of lung cancer have markedly increased due to the aging of the population and continuous increase in tobacco consumption in China [1,2,3,4]. Although cigarette smoking is the major cause of lung cancer and contributes to more than 80% of cases [5], only a small fraction of smokers develop lung cancer. This finding indicates that genetic factors also affect the risk of lung cancer. Although efforts have been made to identify the genetic factors for lung cancer, current knowledge to assess lung cancer risk remains limited.

Recently, some genome-wide association studies (GWAS) have found that variants on chromosome 8q24 are related to the risk of several cancers, including breast, prostate, bladder, colorectal, and ovarian cancers, among multiple study populations [6,7,8,9,10,11,12,13,14,15,16,17]. In addition, variants on 8q24 have been found to be associated with susceptibility to upper gastrointestinal cancer [18,19,20], osteosarcoma [21], thyroid cancer [22,23,24], and brain cancer [25]. This region spans approximately 600 kb and is considered as a gene-poor area, with relatively few predicted genes, including DQ486513, CB104826, and DQ515897, as well as pseudogene POU5F1P1. The proto-oncogene v-myc myelocytomatosis viral oncogene homolog (avian) (MYC) has been determined to be the cancer-related gene closest to the region associated with cancer in GWAS. Transcriptional enhancers in this region have been demonstrated to physically interact with the MYC promoter [26,27] and potentially be affected by cancer-associated variants [28].

Three adjacent genomic blocks (regions 1–3) on 8q24 have been associated with prostate cancer risk [29]. The most significant single-nucleotide polymorphisms (SNPs) are rs1447295 in region 1, rs16901979 in region 2, and rs6983267 in region 3 [29]. These SNPs and additional 8q24 variants have been validated by subsequent association studies. Moreover, these SNPs have been found to be associated with other cancers [9,8,18,19,20,21,30]. Since the 8q24 chromosomal region is commonly amplified in lung cancer tissues [31,32,33,34], genetic variants on 8q24 may be associated with lung cancer susceptibility. Furthermore, SNPs on
8q24 may affect the expression levels of cancer-related genes [26,27,35], which are believed to play roles in lung cancer carcinogenesis. In the present study, we selected one SNP from each region to evaluate the potential association of these SNPs with lung cancer in Han Chinese.

Results

Population characteristics
The characteristics of the lung cancer patients and control subjects enrolled in this study are summarized in Table 1. More men than women were included among the case patients and control subjects, but sex differences between these groups were not significant ($P>0.05$), suggesting their adequate matching. The average age of the population was 58.2 years, and no significant difference in age was found between controls and lung cancer patients ($P>0.05$). Histological type of lung cancer between two patient groups did not significantly differ ($P>0.05$), but significant differences in stage and grade were detected (all $P<0.05$).

Association analysis of rs1447295, rs16901979, and rs6983267 on 8q24
The genotype distributions of the SNPs rs1447295, rs16901979, and rs6983267 were in Hardy–Weinberg equilibrium (HWE) in both cases and controls. In the test set, the frequency of the rs6983267 GG genotype was markedly higher in lung cancer patients (24.9%) than in control subjects (20.5%) (Table 2). The GG genotype was associated with a modestly increased risk [odds ratio (OR) = 1.532, 95% confidence interval (CI) 1.090–2.153, $P=0.014$]. Similarly, in the validation set, the rs6983267 GG genotype was associated with a 1.591-fold increase in the risk of lung cancer ($P=0.010$). Although not statistically significant, the rs6983267 GT genotype also increased the risk of lung cancer ($P=0.062$). However, there were no significant differences between the remaining two SNPs (rs1447295 and rs16901979) and lung cancer in both populations. The final pooled analysis showed that the rs6983267 GG genotype (OR = 1.555, 95% CI = 1.218–1.996, $P=4.0 \times 10^{-4}$) and GT genotype (OR = 1.311, 95% CI = 1.066–1.613, $P=0.01$) were associated with significantly increased risk of lung cancer. After the GG and GT genotypes were combined, the difference remained statistically significant (OR = 1.386, 95% CI = 1.141–1.684, $P=0.001$). Moreover, the associations remained significant even after Bonferroni correction (i.e., $P<0.05/3 = 0.0167$).

The analyses stratified by histology using pooled case-control sets showed that the rs1447295 AA genotype as well as the rs6983267 GG and GT genotypes were associated with a weak but significant increase in the risk of adenocarcinoma adjusted for age,

| Characteristic | Population 1 | Population 2 | Overall |
|---------------|--------------|--------------|---------|
|               | Cases (%) | Controls (%) | Cases (%) | Controls (%) | Cases (%) | Controls (%) |
| Total         | 548       | 556         | 453       | 507         | 1001      | 1063       |
| Age (years)   |           |             |           |             |           |             |
| Median (25% quartile B75% quartile) | 58 (51–64) | 58 (52–64) | 0.756 | 58 (52–64) | 59 (53–65) | 0.148 | 58 (52–64) | 58 (52–65) | 0.079 |
| Gender        |           |             |           |             |           |             |
| Male          | 376 (68.6) | 389 (70.0)  | 323 (71.3) | 339 (66.9) | 699 (69.8) | 728 (68.5) |
| Female        | 172 (31.4) | 167 (30.0)  | 130 (28.7) | 168 (33.1) | 302 (30.2) | 335 (31.5) |
| Smoking status|           |             |           |             |           |             |
| Never         | 223 (41.0) | 283 (52.9)  | 157 (34.7) | 256 (50.6) | 380 (38.1) | 539 (51.8) |
| Current       | 231 (42.5) | 203 (37.9)  | 178 (39.3) | 164 (32.4) | 409 (41.0) | 367 (35.3) |
| Former        | 86 (15.8)  | 43 (8.0)    | 66 (14.6)  | 47 (9.3)   | 152 (15.2) | 90 (8.6)   |
| Unknown       | 4 (0.7)    | 6 (1.1)     | <0.001    | 52 (11.5)  | 39 (7.7)   | <0.001    |
| Stage at diagnosis |           |             |           |             |           |             |
| I             | 135 (24.6) | 83 (18.3)   | 218 (21.8) |              |           |             |
| II            | 99 (18.1)  | 63 (13.9)   | 162 (16.2) |              |           |             |
| III           | 172 (31.4) | 190 (41.9)  | 362 (36.2) |              |           |             |
| IV            | 111 (20.3) | 113 (24.9)  | 224 (22.4) |              |           |             |
| Missing       | 31 (5.7)   | 4 (0.9)     | 35 (3.5)   |              |           |             |
| Grade         |           |             |           |             |           |             |
| Grade 1+2     | 336 (61.3) | 253 (55.8)  | 589 (58.8) |              |           |             |
| Grade 3       | 167 (30.5) | 195 (43.0)  | 362 (36.2) |              |           |             |
| Missing       | 45 (8.2)   | 5 (1.1)     | 50 (5.0)   |              |           |             |
| Histology     |           |             |           |             |           |             |
| Squamous cell carcinoma | 129 (23.5) | 113 (24.9)  | 242 (24.2) |              |           |             |
| Adenocarcinoma| 348 (63.5) | 298 (65.8)  | 646 (64.5) |              |           |             |
| Adenosquamous | 13 (2.4)   | 10 (2.2)    | 23 (2.3)   |              |           |             |
| Others        | 58 (10.6)  | 32 (7.1)    | 90 (9.0)   |              |           |             |

doi:10.1371/journal.pone.0041930.t001

Polymorphisms on 8q24 and Lung Cancer

PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e41930
Table 2. Association between three SNPs in 8q24 and risk of lung cancer.

| SNP          | Genotype | Test set (548/556) | Validation set (453/507) | Pooled (1001/1063) |
|--------------|----------|--------------------|--------------------------|--------------------|
|              |          | No. a OR (95% CI)b  | No. a OR (95% CI)b        | No. a OR (95% CI)b  |
|              |          |                    |                           |                    |
| rs1447295    | CC       | 406/407 Reference   | 323/381 Reference         | 729/788 Reference |
|              | AC       | 129/139 0.933 (0.708–1.231) 0.625 | 116/118 1.166 (0.866–1.568) 0.312 | 245/257 1.033 (0.844–1.264) 0.756 |
|              | AA       | 13/10 1.336 (0.578–3.087) 0.498 | 14/8 2.172 (0.896–5.268) 0.086 | 27/18 1.678 (0.915–3.079) 0.094 |
|              |          |                    |                           | 0.079              |
|              |          | 0.167              | 0.032                    | 0.019              |
| rs16901979   | CC       | 263/285 Reference   | 209/248 Reference         | 472/533 Reference |
|              | AC       | 237/228 1.128 (0.880–1.444) 0.342 | 208/215 1.152 (0.883–1.502) 0.298 | 445/443 1.138 (0.950–1.364) 0.162 |
|              | AA       | 48/43 1.215 (0.779–1.896) 0.39 | 36/44 0.963 (0.596–1.554) 0.876 | 84/87 1.091 (0.789–1.510) 0.598 |
|              |          |                    |                           | 0.655              |
|              |          | 0.321              | 0.392                    | 0.807              |
| rs6983267    | TT       | 135/173 Reference   | 115/164 Reference         | 250/337 Reference |
|              | GT       | 276/269 1.285 (0.967–1.708) 0.084 | 214/231 1.335 (0.986–1.809) 0.062 | 490/500 1.311 (1.066–1.613) 0.010 |
|              | GG       | 136/114 1.532 (1.090–2.153) 0.014 | 123/112 1.591 (1.118–2.264) 0.010 | 259/226 1.555 (1.218–1.986) 4.0 × 10⁻⁴ |
|              |          |                    |                           | 0.013              |
|              |          | 0.34 × 10⁻⁴        | 0.009                    | 0.048              |

aCases/controls.  
bAdjusted for age, sex and smoking status.

doi:10.1371/journal.pone.0041930.t002

sex, and smoking status [OR = 2.260, 95% CI 1.174–4.353, P = 0.015; OR = 1.330, 95% CI 1.003–1.763, P = 0.048; OR = 1.327, 95% CI 1.049–1.679, P = 0.018, respectively] (Table 3). The rs6983267 GG genotype was associated with squamous cell carcinoma risk [OR = 1.775, 95% CI 1.201–2.625, P = 0.004]. In addition, individuals with the rs6983267 GG or GT genotype were at significantly increased risk of other types of lung cancer [OR = 1.45, 95% CI 1.201–2.625, P = 0.032). However, this association has not been assessed in current-smokers.

In the present study, we examined whether SNPs on chromosome 8q24 related to susceptibility to breast, prostate, bladder, colorectal, thyroid, and ovarian cancers [6,7,8,9,10,11,12,13,14,15,16,23] are also associated with risk of lung cancer in Han Chinese populations. We found that the TT genotype of rs6983267 was significantly associated with increased risk of lung cancer and decreased survival in Han Chinese.

8q24 aberration is a frequent event in lung cancer [31,32,33,34]. MYC, localized at 8q24.1, is a well-established oncogene involved in cell growth, proliferation, differentiation, and apoptosis. Deregulated overexpression of MYC is responsible for a wide range of human cancers. The rs6983267 is located 335 kb upstream from the MYC gene. Recent studies have demonstrated that rs6983267 maps to transcription factor 7-like 2 (TCF7L2) motif and forms long-range interactions with MYC [27,36]. Compared with the T allele of rs6983267, the G allele has been reported to have stronger TCF7L2 binding in vitro and in vivo and to enhance Wnt activity [36,37]. Furthermore, many studies have shown that the GG genotype of rs6983267 is associated with a significantly higher risk of several cancers [9,30,38]. Park et al. [20] reported no association between rs6983267 and lung cancer patients and 1910 control subjects and found that the GG genotype after adjusted for age, sex, smoking status, tumor stage, histology and histological grade (HR = 1.646, 95% CI 1.099–2.464, P = 0.016 (Table 5). The survival was poor especially for patients with stage III or IV tumor (HR = 1.993, 95% CI 1.128–3.521, P = 0.018) (Figure 1B). No other SNP was found to be associated with survival. No association with survival in the Fujian population was observed.

Discussion

In the present study, we examined whether SNPs on chromosome 8q24 related to susceptibility to breast, prostate, bladder, colorectal, thyroid, and ovarian cancers [6,7,8,9,10,11,12,13,14,15,16,23] are also associated with risk of lung cancer in Han Chinese populations. We found that the GG genotype of rs6983267 was significantly associated with increased risk of lung cancer and decreased survival in Han Chinese.
rs16901979 and rs6983267) and found that only rs6983267 was significantly associated with an increased risk of lung cancer in Han Chinese. These findings were different from previous studies in which there were no significant correlations between rs6983267 and lung cancer [20,38]. Since the effect of a low-penetrance susceptibility gene on disease risk can be modified by other genes as well as by environmental factors, ethnic differences in genetic backgrounds and different risk factors might explain, to some extent, the discrepant results. Furthermore, rs6983267 was most significantly associated with other histological types of lung cancer, followed by squamous cell carcinoma, and weakly but significantly associated with adenocarcinoma. These results indicated that different mechanisms may exist in the molecular pathogenesis of the various histological types of lung cancer.

Exposure to tobacco carcinogens may induce severe DNA damage and thus promote tumor formation. In this study, we found that the increased risk of lung cancer with rs6983267 GG genotype was more pronounced among non-smokers, whereas no significant correlations were found in current- and former-smokers. One possible explanation for this is that never-smokers may be more likely to have been exposed to unknown risk factors associated with lung cancer, such as environmental pollutants. There may exist different carcinogenesis mechanisms between never and current-/former- smokers. Our result is different from previous study, in which rs6983267 GG was a risk factor in ever-smoker [20]. Different study populations and analytical approaches could account for the contradictory results. In addition, we found a significant association of the A allele of rs1447295 with a

Table 3. Genotype distribution of three SNPs by histology in patients and controls.

| SNP       | Genotype | Adenocarcinoma | | Squamous cell carcinoma | | Others | |       |
|-----------|----------|----------------|---------------|------------------------|---------------|----------|---------------|-----------|
|           | No. a OR (95% CI) | p<sub>b</sub> | No. a OR (95% CI) | p<sub>b</sub> | No. a OR (95% CI) | p<sub>b</sub> | No. a OR (95% CI) | p<sub>b</sub> |
| rs1447295 | CC 451/788 Reference | 192/788 Reference | 82/788 Reference | | | | | |
|           | AC 173/257 1.243 (0.989–1.563) 0.063 | 44/257 0.716 (0.496–1.035) 0.076 | 28/257 1.048 (0.665–1.651) 0.840 | | | | | |
|           | AA 22/18 2.260 (1.174–4.353) 0.015 | 2/18 0.555 (0.124–2.480) 0.440 | 3/18 1.781 (0.502–6.311) 0.371 | | | | | |
| P value for trend | 0.005 | 0.057 | 0.427 | | | | | |
| rs16901979 | CC 295/533 Reference | 118/533 Reference | 56/533 Reference | | | | | |
|           | AC 286/443 1.189 (0.965–1.465) 0.103 | 109/443 1.088 (0.805–1.469) 0.584 | 49/443 1.053 (0.704–1.573) 0.803 | | | | | |
|           | AA 65/87 1.350 (0.946–1.926) 0.098 | 11/87 0.546 (0.279–1.069) 0.077 | 8/87 0.678 (0.297–1.543) 0.354 | | | | | |
| P value for trend | 0.041 | 0.036 | 0.747 | | | | | |
| rs6983267 | TT 165/337 Reference | 66/337 Reference | 19/337 Reference | | | | | |
|           | GT 328/500 1.327 (1.049–1.679) 0.018 | 100/500 1.018 (0.718–1.445) 0.919 | 58/500 1.986 (1.157–3.408) 0.013 | | | | | |
|           | GG 151/226 1.330 (1.003–1.763) 0.048 | 72/226 1.775 (1.201–2.625) 0.004 | 36/226 3.012 (1.675–5.417) 2.3×10<sup>-4</sup> | | | | | |
| P value for trend | 0.035 | 0.006 | 1.9×10<sup>-4</sup> | | | | | |

<sup>a</sup>cases/controls.<br><sup>b</sup>Adjusted for age, gender and smoking status.<br>doi:10.1371/journal.pone.0041930.t003

Table 4. Genotype distribution of three SNPs by smoking status in patients and controls.

| SNP       | Genotype | Never | | Current | | Former | |       |
|-----------|----------|-------|---------------|----------|---------------|----------|-------|---------------|-----------|
|           | No. a OR (95% CI) | p<sub>b</sub> | No. a OR (95% CI) | p<sub>b</sub> | No. a OR (95% CI) | p<sub>b</sub> | No. a OR (95% CI) | p<sub>b</sub> |
| rs1447295 | CC 275/407 Reference | 295/278 Reference | 121/61 Reference | | | | | |
|           | AC 95/122 1.127 (0.820–1.548) 0.461 | 104/82 1.173 (0.840–1.639) 0.349 | 28/29 0.478 (0.254–0.898)<sup>c</sup> 0.022<sup>c</sup> | | | | | |
|           | AA 10/10 1.588 (0.623–4.045) 0.333 | 10/7 1.463 (0.543–3.942) 0.451 | 3/0 | | | | | |
| P value for trend | 0.270 | 0.249 | 0.022 | | | | | |
| rs16901979 | CC 175/283 Reference | 197/181 Reference | 79/41 Reference | | | | | |
|           | AC 168/207 1.288 (0.968–1.715) 0.083 | 184/154 1.122 (0.834–1.510) 0.446 | 60/46 0.674 (0.380–1.193) 0.175 | | | | | |
|           | AA 37/49 1.049 (0.654–1.682) 0.843 | 28/32 0.803 (0.464–1.390) 0.433 | 13/3 2.650 (0.660–10.640) 0.169 | | | | | |
| P value for trend | 0.302 | 0.937 | 0.991 | | | | | |
| rs6983267 | TT 95/170 Reference | 100/118 Reference | 42/27 Reference | | | | | |
|           | GT 174/274 1.160 (0.841–1.600) 0.366 | 203/167 1.446 (1.032–2.027) 0.032 | 74/40 1.509 (0.782–2.912) 0.220 | | | | | |
|           | GG 114/95 2.366 (1.605–3.488) 1.4×10<sup>-5</sup> | 104/82 1.430 (0.962–2.126) 0.077 | 36/23 1.180 (0.558–2.495) 0.665 | | | | | |
| P value for trend | 2.8×10<sup>-5</sup> | 0.063 | 0.498 | | | | | |

<sup>a</sup>cases/controls.<br><sup>b</sup>Adjusted for age and gender.<br><sup>c</sup>AA+AC vs CC.<br>doi:10.1371/journal.pone.0041930.t004
low risk of lung cancer in former-smokers. However, Park et al. found that this allele was associated with a higher risk of liver cancer in ever-smokers [20]. Since the number of former-smokers in this population was very small for a case-control association study, our findings on the A allele of rs1447295 are most likely false positive due to multiple comparisons. Caution should be used in interpreting this result even though it is statistically significant. Further studies with larger numbers of subjects are needed to confirm these findings.

MYC amplification has been shown to be correlated with poor prognosis of patients with lung cancer [31,32,34]. Since the risk allele rs6983267 G has been shown to have a stronger affinity to TCF7L2 and may induce enhanced MYC expression [27,36], rs6983267 might be associated with survival in patients with lung cancer. In this study, we found that rs6983267 GG genotype was associated with markedly worse survival in the Zhejiang population. This effect was more pronounced in patients with stage III or IV tumor. This result is in accordance with the functional consequences of this polymorphism. In contrast, no association was found between rs6983267 and survival in the Fujian population. Part of this disparity may be explained by the distinct percentages of disease stage and histological grade as well as the different treatment approaches used. Cicek et al. examined 393 patients with colon cancer and found no association between rs6983267 and survival [39]. However, Dai et al. examined 170 patients with colorectal cancer and found that T allele was

![Figure 1. Kaplan–Meier survival curves for lung cancer patients in the Zhejiang study population with different rs6983267 genotypes.](https://doi.org/10.1371/journal.pone.0041930.g001)

### Table 5. Association between three SNPs on 8q24 and survival in patients with lung cancer.

| SNP            | Genotype | Zhejiang population | Fujian population |
|----------------|----------|---------------------|-------------------|
|                | No. of patients | No. of death (%) | HR (95% CI)* | P* | No. of patients | No. of death (%) | HR (95% CI)* | P* |
| rs1447295      | CC       | 209                 | 153 (72.9) | Reference | 255 | 169 (73.2) | Reference | 0.201 | 0.958 |
|                | AC       | 70                  | 52 (24.8)  | 0.983 (0.712–1.358) | 0.918 | 79 | 53 (22.9)  | 1.025 (0.751–1.399) | 0.877 |
|                | AA       | 6                   | 5 (2.4)    | 2.272 (0.916–5.634) | 0.077 | 15 | 9 (3.9)    | 1.097 (0.548–2.193) | 0.794 |
|                | Global P value | 0.201      | | | | | 0.958 | |
| rs16901979     | CC       | 139                 | 99 (47.1)  | Reference | 165 | 109 (47.2) | Reference | 0.876 | 0.224 |
|                | AC       | 119                 | 90 (42.9)  | 1.079 (0.807–1.444) | 0.607 | 160 | 105 (45.5) | 0.969 (0.739–1.2720 | 0.823 |
|                | AA       | 27                  | 21 (10.0)  | 1.041 (0.635–1.705) | 0.874 | 24 | 17 (7.4)   | 1.524 (0.907–2.561) | 0.111 |
|                | Global P value | 0.876      | | | | | 0.224 | |
| rs6983267      | TT       | 75                  | 49 (23.3)  | Reference | 89 | 61 (26.4)  | Reference | 0.049 | 0.464 |
|                | GT       | 140                 | 105 (50.0) | 1.411 (0.986–2.018) | 0.060 | 158 | 110 (47.6) | 1.081 (0.750–1.558) | 0.675 |
|                | GG       | 70                  | 56 (26.7)  | 1.646 (1.099–2.464) | 0.016 | 100 | 60 (26.0)  | 1.218 (0.884–1.678) | 0.227 |
|                | Global P value | 0.049      | | | | | 0.464 | |

*adjusted for age, sex, smoking status, tumor stage, histology and histological grade.

doi:10.1371/journal.pone.0041930.t005
associated with worse survival [40]. These results suggest that a more complex or tumor-specific relationship may exist. As our study was limited to Han Chinese with lung cancer, the results may not be generalizable to other ethnicities. In addition, the sample size for survival analysis was relatively small, thereby prompting cautious interpretation of our results. Further research in a larger population group is necessary to clarify this relationship.

In summary, the findings of our study suggest that the SNPs on 8q24 are associated with susceptibility to lung cancer in Han Chinese. In addition, rs6983267 GG genotype was associated with poor survival in the Zhejiang population. To our knowledge, this is the first study that investigated potential associations between SNPs on 8q24 and lung cancer in a population from East China. Additional large studies are warranted to improve our understanding of the contributions of genetic factors to lung cancer.

Materials and Methods

Subjects

In this study, we performed an association study in two independent sets of subjects. The test set included 548 lung cancer patients and 556 control subjects. The case patients had a diagnosis of lung cancer confirmed on histology and were recruited from Taizhou Central Hospital, Zhejiang, between 2003 and 2010. The cancer-free control subjects were hospital visitors who came to the health examination clinic for an annual check-up between 2007 and 2010. The validation set consisted of 453 lung cancer patients and 507 control subjects from Fujian Province. The case patients were consecutive patients with histologically confirmed lung cancer enrolled from Fuzhou Pulmonary Hospital between 2008 and 2010. The control subjects were cancer-free individuals selected from a pool of healthy volunteers who visited the hospital during the period of 2008–2010. Epidemiological data were collected by trained interviewers who were not aware of the group assignments using a specific standardized questionnaire to obtain detailed information on the participants demographic factors, personal habits, medical history, family history of cancer, as well as history of occupational and environmental exposure. Study subjects were classified into three groups based on their smoking status. Never-smokers were those who indicated that they had smoked less than 100 cigarettes in their lifetime and were not current-smokers. Smokers were classified into former smokers and current smokers. Former-smokers were those who reported smoking at least 100 cigarettes during their lifetime and were not current-smokers, whereas current-smokers were those who reported that they were still smoking at the time of their lung cancer diagnosis. Individuals known to have a family history of cancer, a history of any cancer other than lung cancer, or metastasized cancer from other or unknown origins were excluded. The control subjects were frequency matched to the case patients based on sex and age (±5 years). All case patients and control subjects were unrelated ethnic Han Chinese. This study was approved by the ethics committees of Taizhou Central Hospital and Fuzhou Pulmonary Hospital, and written informed consent was obtained from all participants before entering the study.

Our end point was overall survival from the initial histological diagnosis. Patients who were alive or lost to follow-up were censored on the date of last contact. Those who died of other causes were censored on the date of their death. Furthermore, patients lost to follow-up in the first year were excluded from analysis.

Genotyping

Blood samples were collected from all study participants. Genomic DNA was extracted using Universal Genomic DNA Extraction Kit Version 3.0 (Takara, Dalian, China) according to the manufacturer’s protocol, and DNA samples were stored at −20°C. We selected the strongest single-association SNPs from each chromosomal region: rs1447295 from region 1, rs16901979 from region 2, and rs6983267 from region 3. Genotyping was performed by polymerase chain reaction-ligation detection reaction (PCR-LDR) method. Primers were designed by software of Primer 3 (http://frodo.wi.mit.edu/primer3/input.htm). The three primer pairs are as following: 1) rs1447295: 5’-GCCTAGCC-TACCTGCTGTCT-3’ (forward) and 5’-CTCCCA-GATTTTCCCATAACC-3’ (reverse); 2) rs16901979: 5’-AGTGTGGGGTCTTTTGTGAGG-3’ (forward) and 5’-CAGCAGTCTCCCTGTCTTGG-3’ (reverse); 3) rs6983267: 5’-ATGAAGGGCTGTCGCAAAATGA-3’ (forward) and 5’-TTGGCTGGCAGCGTCTGATATA-3’ (reverse). Amplification reactions were carried out in a final reaction volume of 15 μL containing 0.3 mmol/L of each deoxynucleoside triphosphate, 10 mmol/L Tris-HCl, 50 mmol/L KCl, 2 mmol/L MgCl₂, 20% Q solution (Qiagen, Hilden, Germany), 0.16 μmol/L of each primer, 10 ng genomic DNA, and 1 U Taq (Takara, Dalian, China). The cycling parameters were: 94°C for 3 min, followed by 10 cycles of 94°C for 30 s, 64°C for 30 s with a 0.5°C decrement of the annealing temperature per cycle and 72°C for 30 s, followed by 30 cycles of 94°C for 30 s, 59°C for 30 s and 72°C for 30 s, and a final extension step at 72°C for 5 min. After amplification, PCR products were incubated with 2 U shrimp alkaline phosphatase (Merck, Darmstadt, Germany) and 4 U exonuclease I (Fermentas, Vilnius, Lithuania) at 37°C for 1 h, and then denatured at 95°C for 10 min.

The LDR primers were: 1) rs1447295: 5’-GTGCCATTTGGG-GAGTTATGAAAA-3’ (A specific primer), 5’-TTTGGCTGGCAGTTGAGTTTGAAC-3’ (G specific primer) and 5’-GTGCTATGGAAAAGCAACAGGA-FAM-3’ (common FAM labeled 3’-end primer); 2) rs16901979: 5’-TTTGTGTAATTGATATTGACATTACCTATTATA-3’ (C specific primer), 5’-TTTTTTTGTATGATATTGACATTACCTATTATA-3’ (G specific primer), 5’-CTGCAGGTTTTTCAGTCTTTTATTACCTATTATA-3’ (T specific primer) and 5’-GATCAGGTTTTCAGTCTTTTATTACCTATTATA-3’ (C specific primer). LDR reactions were carried out in a final reaction volume of 15 μL containing 0.3 mmol/L of each deoxynucleoside triphosphate, 10 mmol/L Tris-HCl, 50 mmol/L KCl, 2 mmol/L MgCl₂, 20% Q solution (Qiagen, Hilden, Germany), 0.16 μmol/L of each primer, 10 ng genomic DNA, and 1 U Taq (Takara, Dalian, China). The cycling parameters were: 94°C for 3 min, followed by 10 cycles of 94°C for 30 s, 74°C for 30 s with a 0.5°C decrement of the annealing temperature per cycle and 72°C for 30 s, followed by 30 cycles of 94°C for 30 s, 59°C for 30 s and 72°C for 30 s, and a final extension step at 72°C for 5 min. After amplification, PCR products were incubated with 2 U shrimp alkaline phosphatase (Merck, Darmstadt, Germany) and 4 U exonuclease I (Fermentas, Vilnius, Lithuania) at 37°C for 1 h, and then denatured at 95°C for 10 min. The LDR primers were: 1) rs1447295: 5’-GTGCCATTTGGG-GAGTTATGAAAA-3’ (A specific primer), 5’-TTTGGCTGGCAGTTGAGTTTGAAC-3’ (G specific primer) and 5’-GTGCTATGGAAAAGCAACAGGA-FAM-3’ (common FAM labeled 3’-end primer); 2) rs16901979: 5’-TTTGTGTAATTGATATTGACATTACCTATTATA-3’ (C specific primer), 5’-CTGCAGGTTTTTCAGTCTTTTATTACCTATTATA-3’ (G specific primer), 5’-GATCAGGTTTTCAGTCTTTTATTACCTATTATA-3’ (T specific primer) and 5’-CAGCAGGAAAAATGTAACAA-AAGTATTITTTTTTTTTT-TTAACAGAATTAA-3’ (C specific primer). LDR reactions were carried out in a final reaction volume of 15 μL containing 0.3 mmol/L of each deoxynucleoside triphosphate, 10 mmol/L Tris-HCl, 50 mmol/L KCl, 2 mmol/L MgCl₂, 20% Q solution (Qiagen, Hilden, Germany), 0.16 μmol/L of each primer, 10 ng genomic DNA, and 1 U Taq (Takara, Dalian, China). The cycling parameters were: 94°C for 3 min, followed by 10 cycles of 94°C for 30 s, 64°C for 30 s with a 0.5°C decrement of the annealing temperature per cycle and 72°C for 30 s, followed by 30 cycles of 94°C for 30 s, 59°C for 30 s and 72°C for 30 s, and a final extension step at 72°C for 5 min. After amplification, PCR products were incubated with 2 U shrimp alkaline phosphatase (Merck, Darmstadt, Germany) and 4 U exonuclease I (Fermentas, Vilnius, Lithuania) at 37°C for 1 h, and then denatured at 95°C for 10 min.
randomly selected samples were genotyped in duplicate and yielded the same results (100% reproducibility).

Statistical analysis

The means of quantitative variables were compared using Student’s t test. Fisher’s exact Chi-square test was used to compare categorical variables between case patients and control subjects. HWE was calculated by the Chi-square test for goodness of fit in both patient and control groups. Correction for multiple testing was carried out using the Bonferroni method. To evaluate the relationship between 3 SNPs and the risk of lung cancer, the ORs and their 95% CIs were estimated by multivariate logistic regression analysis, adjusted by age, sex, and smoking status, to evaluate the relationship between each of the three SNPs and the risk of lung cancer. Survival analysis was performed using the Kaplan–Meier method with log-rank test. Cox proportional hazards models were also used to adjust for age, sex, smoking status, tumor stage, histology, and histological grade. P<0.05 was considered statistically significant. All tests were two-sided, and all statistical analyses were performed with SPSS 17.0 software package (SPSS Inc, Chicago, USA).

Author Contributions

Conceived and designed the experiments: XLZ BFC. Performed the experiments: CYH WHM LZ. Analyzed the data: XLZ QC. Contributed reagents/materials/analysis tools: XWX JZ. Wrote the paper: XLZ QC BFC.

References

1. Chen W, Zhang S, Zou X (2010) [Estimation and projection of lung cancer incidence and mortality in China]. Zhongguo Fei Ai Za Zhi 13: 480–493.
2. Yang L, Parkin DM, Li L, Chen Y. (2003) Trend in cancer mortality in China: 1987-1999. Int J Cancer 106: 771–783.
3. Yang L, Parkin DM, Ferlay J, Li L, Chen Y (2005) Estimates of cancer incidence in China for 2000 and projections for 2050. Cancer Epidemiol Biomarkers Prev 14: 213–250.
4. Zhang H, Cai B (2003) The impact of tobacco on lung health in China. Respirology 8: 17–21.
5. Parkin DM, Pisani P, Lopez AD, Masuyer E (1994) At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int J Cancer 59: 494–504.
6. Goode EL, Chenive-Trench G, Song H, Ramus SJ, Notaridou M, et al. (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 8q21 and 8p23. Nat Genet 42: 674–679.
7. Haiman CA, Le Marchand L, Yamamoto Y, Stram DO, Sheng X, et al. (2007) A common genetic risk factor for colorectal and prostate cancer. Nat Genet 39: 934–936.
8. Zanke BW, Greenwood CM, Rangej J, Kustra R, Tenesa A, et al. (2007) Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 39: 989–994.
9. Tomlinson I, Webb E, Carvalj-Carmo L, Broderick P, Kemp Z, et al. (2007) A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24. Nat Genet 39: 984–988.
10. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, et al. (2010) A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 42: 978–984.
11. Turnbull C, Ahmed S, Morrison J, Perner D, Renvick A, et al. (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42: 504–507.
12. Erles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, et al. (2009) Identification of some new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 41: 1116–1121.
13. Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, et al. (2009) Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 41: 1035–1060.
14. Yeager M, Chatterjee N, Giampi J, Jacobs KB, Gonzalez-Bosquet J, et al. (2009) Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet 41: 1055–1057.
15. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087–1093.
16. Ciampi J, Yeager M, Amundadottir L, Jacobs K, Kraft P, et al. (2011) Large-scale exploration of gene-gene interactions in prostate cancer using a multistage genome-wide association study. Cancer Res 71: 3267–3275.
17. Kim HC, Lee JY, Sung H, Choi JY, Park SK, et al. (2012) A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q14: results from the Seoul Breast Cancer Study. Breast Cancer Res 14: R56.
18. Lochhead P, Ng MT, Holt GL, Rabkin CS, Vaughan TL, et al. (2011) Possible association between a genetic polymorphism at 8q24 and risk of upper gastrointestinal cancer. Eur J Cancer Prev 20: 34–37.
19. Guo Y, Fang J, Liu Y, Sheng HH, Zhang XY, et al. (2011) Association between polymorphisms rs6983267 and gastric cancer risk in Chinese population. World J Gastroenterol 17: 1759–1765.
20. Park SL, Chang SC, Cai L, Cordorn-Cardo C, Ding BG, et al. (2008) Associations between variants of the 8q21 chromosome and nine smoking-related cancer sites. Cancer Epidemiol Biomarkers Prev 17: 3191–3202.
21. Mirabello L, Berndt SI, Serati GF, Burdett L, Yeager M, et al. (2010) Genetic variation at chromosome 8q24 in osteosarcoma cases and controls. Carcinogenesis 31: 1400–1404.
22. He H, Naga R, Lianarachi S, Jiao H, Li W, et al. (2009) A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Res 69: 625–631.
23. Jones AM, Howarth KM, Martin L, Gorman M, Mihai R, et al. (2012) Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q12. J Med Genet 49: 153–159.
24. Neta G, Yu CL, Beamur A, Gu F, Hutchinson A, et al. (2012) Common genetic variants in the 8q24 region and risk of papillary thyroid cancer. Laryngoscope 122: 1040–1042.
25. Guarnera S, Ricci F, Polidoro S, Sacerdote C, Allione A, et al. (2012) Association between total number of deaths, diabetes mellitus, incident cancers, and haplotypes in chromosomal region 8q24 in a prospective study. Am J Epidemiol 175: 479–487.
26. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, et al. (2009) Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res 69: 5568–5574.
27. Pomerantz MM, Ahmadinjou D, Li J, Herman P, Verzi MP, et al. (2009) The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 41: 882–884.
28. Wasserman NF, Aneja I, Nobrega MA (2010) An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Res 20: 1191–1197.
29. Wine J (2007) Multiple prostate cancer risk variants on 8q24. Nat Genet 39: 579–580.
30. Darazi A, Salehi R, Salehi M, Emami MH, Jonghorbani M, et al. (2012) Effect of rs6983267 polymorphism in the 8q24 region and rs1444903 polymorphism in EGF gene on the risk of sporadic colorectal cancer in Iranian population. Med Oncol 29: 1044–1049.
31. Kang JU, Koo SH, Kwon KC, Park JW, Shin SY, et al. (2007) High frequency of genetic alterations in non-small cell lung cancer detected by multi-target fluorescent in situ hybridization. J Korean Med Sci 22 Suppl: 547–54.
32. Ikawa R, Kohno T, Kato M, Shiraiishi K, Tsuba K, et al. (2011) MYC amplification as a prognostic marker of early-stage lung adenocarcinoma identified by whole genome copy number analysis. Clin Cancer Res 17: 1401–1409.
33. Capuzzo F, Varella-Garcia M, Rossi E, Gajapathy S, Valente M, et al. (2009) MYC and E2F3/2F4Coaplication significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. J Thorac Oncol 4: 472–478.
34. Kubokura H, Tenjini T, Aiikuya H, Koizumi N, Nishimura H, et al. (2001) Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization. Ann Thorac Cardiovasc Surg 7: 197–203.
35. Meyer KB, Maia AT, O’Reilly M, Ghossaini M, Prathalingam R, et al. (2011) A Functional Variant at a Prostate Cancer Predisposition Locus at 8q24 Is Associated with PVT1 Expression. PLoS Genet 7: e1002165.
36. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, et al. (2009) The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 41: 882–884.
37. Wright JB, Brown SJ, Cole MD (2010) Upregulation of c-MYC in cis through a BFC. reagents/materials/analysis tools: XWX JZ. Wrote the paper: XLZ QC. Performed the experiments: CYH WHM LZ. Analyzed the data: XLZ QC. Contributed